Biogen Inc (BIIB.OQ)
320.14USD
13 Dec 2018
$-2.47 (-0.77%)
$322.61
$323.97
$325.65
$319.18
428,404
488,077
$388.67
$249.24
About
Overall
| Beta: | 0.72 |
| Market Cap(Mil.): | $69,239.67 |
| Shares Outstanding(Mil.): | 211.43 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BIIB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 21.50 | 31.13 | 34.39 |
| EPS (TTM): | 15.23 | -- | -- |
| ROI: | 17.59 | 15.55 | 14.96 |
| ROE: | 28.64 | 16.92 | 16.52 |
Novartis's pricing might be tested with costly eye therapy
ZURICH Novartis's price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting gene therapy whose $850,000 list cost in the United States has been labeled too expensive by some groups.
UPDATE 1-Novartis's pricing might be tested with costly eye therapy
* Swiss drugs group forging into pricey rare-disease meds (Adds comments, context about pricing, analyst quote)
Eisai, Biogen Alzheimer's data fails to convince skeptics
Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.
UPDATE 2-Eisai, Biogen Alzheimer's data fails to convince skeptics
Oct 25 Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.
UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince
Oct 25 Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.
Biogen/Eisai Alzheimer's data suggests treatment effect related to drug
Oct 25 Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.
UPDATE 1-Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Oct 24 A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.
Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
Oct 24 A U.S. appeals court on Wednesday upheld a ruling that patents owned by Biogen Inc covering its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.
Estimates